The approval is for strengths of 0.1 mg and 0.2 mg
Glenmark Pharmaceuticals has said that the US Food and Drug Administration (US FDA) has approved its generic version of desmopressin acetate tablets used in the treatment of diabetes and bed-wetting.
The approval is for strengths of 0.1 mg and 0.2 mg.
Desmopressin acetate is sold under the trademark DDAVP by Ferring Pharmaceuticals. Accordint to IMS data, DDAVP market achieved annual sales of approximately $72.1million in the 12 month period ended March 2015.